Study S000598

Feasibility of Once-daily Administered GLP-1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin in Patients With Type-2 Diabetes Mellitus Not Achieving Therapeutic Targets With Premixed Insulin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02168491
Acronym: LixiBIT
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 10
Start: 2014-11
Primary completion: 2015-07
Lead sponsor: Medical University of Vienna
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Lixisenatide; DRUG:Insulin glargine
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2013-005334-37

Registered primary outcomes

Change in HbA1c From Baseline to End [12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022051	Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients. Harreiter J, Diabetes therapy : research, treatment and education of diabetes and related disorders	2017	Other trial	PMID 28357772 DOI	cites ClinicalTrials.gov:NCT02168491; cites EudraCT:2013-005334-37; registry reference DERIVED:28357772